Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: A dose-finding study

Breast Cancer Research and Treatment

Volumn 80, Issue 3, 2003, Pages 257-265

  Esteban, Emilio ^a   Modollel, Antonio ^a   De Sande, Luis González ^a   Palacio, Isabel ^a   Muñiz, Isabel ^a   Fernández, Yolanda ^a   Corral, Norberto ^a   Fra, Joaquin ^a   Sala, Marian ^a   Vieitez, Jose María ^a   Estrada, Enrique ^a   Lacave, A J ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Advanced breast cancer; Combination chemotherapy; Docetaxel; Epirubicin; Vinorelbine

Indexed keywords

DOCETAXEL; EPIRUBICIN; NAVELBIN; NAVELBINE;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER TOXICITY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FEVER; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NAUSEA; NEUTROPENIA; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE; VOMITING;

EID: 0041322812     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024985309383     Document Type: Article

References (26)

1. Honig SF: Treatment of metastatic disease. In: Harris JR, Hellman S, Henderson IC, Kline D (eds) Breast Diseases. Lippincott, Philadelphia, PA, 1996, pp 669-734
2. A'Hem RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion doxorubicin in Cooper type regimens. Br J Cancer 67: 801-805, 1993
3. Brambilla C, Rossi A, Bonfante V, Ferrari L, Villani F, Crippa F, Bonadonna G: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261-266, 1986
4. Mouridsen HT: Systemic therapy of advanced breast cancer. Drugs 44(Suppl 4): 17-28, 1992
5. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, Garcia-Giralt E, Keiling R, Namer M, Closon MT: Phase II trial of weekly intravenous vinorelbine in first line advanced breast cancer chemotherapy. J Clin Oncol 11: 1245-1252, 1993
6. Garcia Conde J, Lluch A, Martin M, Casado A, Gervasio MH, de Oliveira C, de Pablo J, Gorostiaga J, Giron GC, Cervantes A, Martinez A, Pezous N, Delgado FM, Diaz-Rubio E: Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 5: 854-857, 1994
7. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, Machiavelli M, Lacava JA, Langhi M, Acuna LR, Amato S, Barbieri R, Sabatini CL, Leone BA: Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12: 336-341, 1994
8. Twelves CJ, Dobbs NA, Curnow A, Coleman R, Stewart A, Tyrelll C, Canney P, Rubens RD: A phase II multicentre UK study of vinorelbine in advanced breast cancer. Br J Cancer 70: 990-993, 1994
9. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, Martine ZL, Fernandez O, Otero J, Kesselring G, Noguera C, Delgado G, Gaubert P, Delgado FM, Solidoro: Phase II trial of weekly IV vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol 18: 392-396, 1995
10. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker JA: Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13: 2722-2730, 1995
11. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 14: 422-428, 1996
12. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is major citotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment. J Clin Oncol 13: 314-322, 1995
13. 2 as first line chemotherapy for patients with advanced breast cancer: report of the clinical screening group of the EORTC. Br J Cancer 74: 650-656, 1996
14. Ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M: A phase II trial of docetaxel in second-line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527-532, 1994
15. Ravdin PM, Burris III HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995
16. Esteban E, González de Sande J, Puertas J, Fra I, Palacio JM, Vieitez JM, Femandez JL, Muniz I, Modollel A, Carrasco J, Sala M, Lacave AJ: A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Res Treat 62: 127-133, 2000
17. Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, Duffy T, Schwartz P, Gottschalk A, Zaret BL: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300: 278-283, 1979
18. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
19. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Eur J Cancer Clin Oncol 13: 89-94, 1977
20. Kaplan E, Meier P: Non-parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958
21. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281-1288, 1984
22. Deplanque G, Dufour P, Essner C, Duclos B, Besançon A, Eichler F, Maglet N, Prévost G, Borel C, Mors R, Brettes JP, Bergerat JP: ATN (Adriamycin-taxotere-navelbine): A phase I-II multicentre study in first line therapy of metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 19(104): 2000 (abstract 401)
23. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN: Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 85: 104-111, 1999
24. Esteban E, Lacave AJ, Fernández JL, Corral N, Buesa JM, Estrada E, Palacio I, Vieitez JM, Muniz I, Alvarez E: Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Res Treat 58: 141-150, 1999
25. Sledge GW, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin (A) vs paclitaxel (T) vs doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer: An intergroup trial. Proc Am Soc Clin Oncol 16(1): 1997 (abstract 2)
26. Norris B, Pritchard KL, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A: Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 18: 2385-2394, 2000